Preferred Label : silodosin;
MeSH note : an alpha(1a)-adrenoceptor-selective antagonist; structure given in first source;
CISMeF synonym : KMD 3213; rapaflo;
MeSH synonym : 1-(3-hydroxypropyl)-5-(2-(2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethylamino)propyl)indoline-7-carboxamide;
MeSH hyponym : KMD-3213;
Is substance : O;
UNII : CUZ39LUY82;
InChIKey : PNCPYILNMDWPEY-QGZVFWFLSA-N;
Origin ID : C095285;
UMLS CUI : C1870115;
ATC code(s)
Automatic exact mappings (from CISMeF team)
MeSH term(s) associated for indexing
Pharmacological action(s)
Record concept(s)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
https://www.has-sante.fr/jcms/p_3422180/fr/urorec-silodosine-hypertrophie-benigne-de-la-prostate
2023
false
false
false
France
insurance, health, reimbursement
silodosin
administration, oral
evaluation of the transparency committee
prostatic hyperplasia
prostatic hypertrophy, benign
silodosin
---
https://www.ema.europa.eu/en/medicines/human/EPAR/silodosin-recordati
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
prostatic hyperplasia
administration, oral
silodosin
silodosin
silodosin
adrenergic alpha-1 receptor antagonists
adrenergic alpha-1 receptor antagonists
urological agents
urological agents
adult
aged
drug interactions
fertility
drug evaluation, preclinical
indoles
indoles
---
http://www.cochrane.org/fr/CD012615/silodosine-pour-le-traitement-des-symptomes-des-voies-urinaires-inferieures-chez-les-hommes
2017
false
false
false
France
United Kingdom
French
french abstract
benign prostatic hypertrophy
hyperplasia of prostate, nos
lower urinary tract symptoms
prostatic hyperplasia
men
therapeutics
prostatic hypertrophy, benign
symptom, nos
silodosin
treaties
urinary tract
lower urinary tract
---
http://www.has-sante.fr/portail/jcms/c_2569213/fr/silodyx
http://www.has-sante.fr/portail/jcms/c_957057/silodyx
2015
false
France
French
prostatic hypertrophy, benign
adult
receptors, adrenergic, alpha-1
silodosin
indoles
administration, oral
silodosin
insurance, health, reimbursement
prostatic hyperplasia
treatment outcome
silodosin
indoles
adrenergic alpha-1 receptor antagonists
adrenergic alpha-1 receptor antagonists
silodosin
silodosin
evaluation of the transparency committee
---
http://www.has-sante.fr/portail/jcms/c_2569219/fr/urorec
http://www.has-sante.fr/portail/jcms/c_957056/urorec
2015
false
France
French
prostatic hypertrophy, benign
adult
silodosin
silodosin
indoles
indoles
receptors, adrenergic, alpha-1
prostatic hyperplasia
administration, oral
insurance, health, reimbursement
treatment outcome
silodosin
adrenergic alpha-1 receptor antagonists
adrenergic alpha-1 receptor antagonists
silodosin
silodosin
evaluation of the transparency committee
---
https://www.ema.europa.eu/medicines/human/EPAR/Urorec
2012
United Kingdom
French
English
syndication feed
indoles
indoles
silodosin
silodosin
capsules
administration, oral
drug approval
treatment outcome
drug labeling
drug interactions
adult
aged
receptors, adrenergic, alpha-1
prostatic hyperplasia
silodosin
adrenergic alpha-1 receptor antagonists
adrenergic alpha-1 receptor antagonists
silodosin
silodosin
drug evaluation
summary of product characteristics
package leaflet
---
https://www.ema.europa.eu/medicines/human/EPAR/Silodyx
2012
United Kingdom
English
French
syndication feed
silodosin
silodosin
indoles
indoles
prostatic hyperplasia
capsules
administration, oral
drug approval
treatment outcome
drug labeling
adult
aged
drug interactions
receptors, adrenergic, alpha-1
silodosin
adrenergic alpha-1 receptor antagonists
adrenergic alpha-1 receptor antagonists
silodosin
silodosin
drug evaluation
package leaflet
summary of product characteristics
---
Summary Basis of Decision (SBD) RAPAFLO - Silodosin, 8 mg and 4 mg capsules
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?lang=fr&linkID=SBD00120
2011
false
Canada
French
English
drug evaluation
indoles
indoles
prostatic hyperplasia
clinical trials, phase iii as topic
randomized controlled trials as topic
silodosin
administration, oral
drug approval
treatment outcome
risk assessment
silodosin
silodosin
adrenergic alpha-1 receptor antagonists
adrenergic alpha-1 receptor antagonists
silodosin
silodosin
---